Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure

doi:10.3969/j.issn.1004-583X.2021.09.003

Abstract

Abstract:

Objective To investigate the clinical effect of sacubitril-valsartan combined with recombinant human brain natriuretic peptide for acute left heart failure(ALHF). Methods A total of 112 ALHF patients admitted to our hospital from June 2018 to October 2020 were by random number table method divided into experimental group (56 cases received sacubitril-valsartan combined with activin) and control group (56 cases received sacubitril-valsartan). After treatment, the total effective rate, heart rate, N-terminal pro-brain natriuretic peptide(NT-proBNP) and left ventricular ejection fraction(LVEF) were analyzed. Malondialdehyde(MDA), superoxide dismutase(SOD) and glutathione peroxidase(GSH-Px) were compared in two groups. Results The total effective rate in experimental group was higher than that of control group (92.86% vs 76.79%, P<0.05). After treatment, the heart rate, NT-proBNP and MDA were lower in experimental group than in control group (P<0.05), while LVEF, SOD and GSH-Px were higher than in control group (P<0.05). Conclusion Sacubitril-valsartan combined with activin can improve cardiac function for ALHF patients, reduce oxidative stress, and stably enhance clinical efficacy.

Key words: heart failure, oxidative stress, drug therapy

CLC Number:

R541.61

Luo Fanglin, Guan Suying, Wu Guoxiang. Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure[J]. Clinical Focus, 2021, 36(9): 782-785.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.09.003

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I9/782

Figures/Tables 3

References 15

[1]	严红芳, 伍莉军. 参附注射液联合冻干重组人脑利钠肽及左西孟旦对急性左心衰竭患者血气指标及肾功能的影响[J]. 中国药物与临床, 2020, 20(22):3767-3769.
[2]	侯江红, 吴秀娟, 王一锦, 等. 芪苈强心胶囊联合硝酸甘油治疗急性左心衰竭的临床研究[J]. 现代药物与临床, 2019, 34(11):3244-3249.
[3]	尚少红, 吕芳. 丹参酮注射液联合无创正压通气治疗急性左心衰竭的疗效及对心功能和炎症反应的影响[J]. 中西医结合心脑血管病杂志, 2019, 17(10):1453-1457.
[4]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[5]	Ahmed A, 杜媛. 一项关于心力衰竭患者纽约心脏协会心功能分级和自然病史终点的倾向匹配研究[J]. 世界核心医学期刊文摘(心脏病学分册), 2007, 3(7):27-28.
[6]	李振军, 郎立国, 任红梅, 等. 托伐普坦片联合沙库巴曲缬沙坦钠片治疗心力衰竭伴低钠血症患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(23):3900-3902+3906.
[7]	Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial[J]. Eur Heart J, 2016, 23(7):425-433.
[8]	王贵强, 袁灵, 杨盛泉, 等. 右美托咪定在急性左心衰治疗应用中的疗效和安全性探讨[J]. 临床药物治疗杂志, 2018, 16(3):33-36.
[9]	邹子扬, 陈金良, 孔令恩, 等. 新活素两种不同给药方法治疗急性左心衰竭的短期疗效前瞻性研究[J]. 中国循证心血管医学杂志, 2017, 9(5):584-587.
[10]	钟文. 参麦注射液联合地高辛对老年急性左心衰竭患者心功能的影响[J]. 医学综述, 2016, 22(17):3481-3483.
[11]	Gorski PA, Ceholski DK, Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure--A rational approach for disease treatment[J]. Cell Metab, 2015, 21(2):183-194. doi: 10.1016/j.cmet.2015.01.005 URL
[12]	杨铁骊, 张卉, 张小方, 等. 参附注射液联合重组人脑利钠肽治疗急性左心衰竭102例疗效观察[J]. 中成药, 2016, 38(8):1875-1877.
[13]	王春玲, 陈阿娣, 田亮, 等. 大剂量西地兰联合小剂量酒石酸美托洛尔治疗急性左心衰并心房颤动的临床疗效[J]. 现代医学, 2016, 44(7):1014-1017.
[14]	Squire IB, Barnett DB. The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy[J]. Br J Clin Pharmacol, 2000, 49(1):1-9.
[15]	潘爱珍, 陈克芳, 侯祥平, 等. 参附注射液联合西药治疗急性左心衰竭(心肾阳虚证)疗效观察[J]. 中国中医急症, 2015, 24(2):347-349.

组别	例数	显效	进步	无效	总有效
实验组	56	28(50.0)	24(42.9)	4(7.1)	52(92.9)
对照组	56	18(32.1)	25(44.7)	13(23.2)	43(76.8)

组别	例数	显效	进步	无效	总有效
实验组	56	28(50.0)	24(42.9)	4(7.1)	52(92.9)
对照组	56	18(32.1)	25(44.7)	13(23.2)	43(76.8)

组别	例数	心率(次/min)		LVEF(%)		NT-proBNP(ng/L)
组别	例数	用药前	用药后	用药前	用药后	用药前	用药后
实验组	56	97.57±6.32	73.71±4.08	30.64±4.72	45.97±5.64	5587.62±256.27	2958.92±149.03
对照组	56	97.84±6.41	84.57±5.72^*	30.85±4.66	37.85±4.92^*	5583.95±260.44	4207.83±214.75^*
t值		0.224	11.567	0.237	8.119	0.075	35.754
P值		0.823	0.000	0.813	0.000	0.940	0.000

组别	例数	心率(次/min)		LVEF(%)		NT-proBNP(ng/L)
组别	例数	用药前	用药后	用药前	用药后	用药前	用药后
实验组	56	97.57±6.32	73.71±4.08	30.64±4.72	45.97±5.64	5587.62±256.27	2958.92±149.03
对照组	56	97.84±6.41	84.57±5.72^*	30.85±4.66	37.85±4.92^*	5583.95±260.44	4207.83±214.75^*
t值		0.224	11.567	0.237	8.119	0.075	35.754
P值		0.823	0.000	0.813	0.000	0.940	0.000

组别	例数	MDA(mmol/L)		SOD(U/L)		GSH-Px(U/L)
组别	例数	用药前	用药后	用药前	用药后	用药前	用药后
实验组	56	19.43±2.17	12.16±1.34	86.52±5.18	98.43±7.92	101.75±7.94	121.93±9.11
对照组	56	19.31±2.20	15.34±1.84^*	86.76±5.72	92.05±6.51^*	101.97±7.69	112.48±8.35^*
t值		0.291	10.455	0.433	4.657	0.149	5.722
P值		0.772	0.000	0.816	0.000	0.882	0.000